2024年上半年，外部环境依然充满挑战，公司按照既定规划，开展新技术和产品的研发申报工作，推出重磅新品完善布局，加大企业和品牌的宣传营销力度，拓展渠道触点并持续优化全渠道运营能力，不忘初心，砥砺前行，为消费者带去更多美好体验，为行业健康发展贡献力量。On August 19th, Gelunhui announced that for the six months ending on June 30, 2024, the company's mid-term performance realized a revenue of 2.54 billion yuan, a 58.2% year-on-year increase, and a net income of 0.98 billion yuan, a 47.2% year-on-year increase, with a basic earnings per share of 0.99 yuan.
The main reason for the overall increase in revenue is that during the reporting period, the company continuously expanded its product types, deepened its online and offline channels, created star products, strengthened marketing, further enhanced the influence of its products and brand, and achieved fast growth in sales revenue.
The company is committed to bringing technology from the laboratory into daily life and becoming a leading enterprise in the field of beauty and health in China. During the reporting period, world-renowned market research firm Euromonitor International issued a statement recognizing the company as a "global leader in recombinant collagen", further consolidating the company's leading position in the field of recombinant collagen worldwide.
In the first half of 2024, the external environment is still full of challenges. The company will carry out the application and declaration of new technologies and products according to established plans, launch heavyweight new products to improve its layout, increase the promotion and marketing efforts of the enterprise and brand, expand channel touchpoints, and continuously optimize its overall channel operation capabilities, stay true to its original intention, and forge ahead to bring consumers more wonderful experiences and contribute to the healthy development of the industry.
Looking forward to the second half of 2024, the company will continue to invest in research and development, further enrich its raw material reserves and product layout, and continue to do a good job in the clinical application and declaration of three categories of medical instruments. The company will take new products and new series as the fulcrum, do a good job in scenario operation, expand asset groups, fully tap into the growth opportunities on various platforms, and lay a foundation for the balanced long-term growth of the brand. The company will increase the development of its enterprise brand, increase its investment in the marketing of its brand, occupy consumers' minds through multi-touchpoints, and promote the company's value proposition. The company hopes to work with its peers to create a brilliant future for Chinese-made and domestic beauty brands.
